From 59459e4bdfdad412c425e0859849c6c8effacb0d Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Thu, 19 Mar 2026 15:49:12 +0000 Subject: [PATCH 1/6] extract: 2025-01-01-produce-prescriptions-diabetes-care-critique Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...l infrastructure connects screening to action.md | 4 ++-- ...ate as four independent methodologies confirm.md | 6 ++++++ ...-produce-prescriptions-diabetes-care-critique.md | 13 ++++++++++++- ...roduce-prescriptions-diabetes-care-critique.json | 12 +++++++----- 4 files changed, 27 insertions(+), 8 deletions(-) diff --git a/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md b/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md index 10345bd13..3d88f6335 100644 --- a/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md +++ b/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md @@ -49,9 +49,9 @@ The Diabetes Care perspective challenges the 'strong ROI' claim for SDOH interve ### Additional Evidence (challenge) -*Source: [[2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026]] | Added: 2026-03-20* +*Source: [[2025-01-01-produce-prescriptions-diabetes-care-critique]] | Added: 2026-03-19* -The RSC's second reconciliation bill proposes site-neutral payments that would eliminate the enhanced FQHC reimbursement rates (~$300/visit vs ~$100/visit) that fund CHW programs. Combined with OBBBA's Medicaid cuts, this creates a two-vector attack on the institutional infrastructure that hosts most CHW programs. The challenge is not just documentation and operational infrastructure—the payment foundation itself is under legislative threat. Even if Z-code documentation improved and operational infrastructure was built, the revenue model that makes CHW programs economically viable within FQHCs would be eliminated by site-neutral payments. +The ADA's Diabetes Care journal questions whether produce prescriptions—a specific SDOH intervention type—generate clinical benefit despite improving food security metrics. Observational studies show diet quality improvements but lack controlled evidence for HbA1c reduction. Programs enrolling patients with very poor baseline control (HbA1c >9%) show improvements that may reflect regression to the mean rather than intervention effect. The clinical diabetes community is signaling that 'food as medicine' framing has outrun the evidence base for this intervention category. --- diff --git a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md index 5ff551fb9..9fdc650f6 100644 --- a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md +++ b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md @@ -65,6 +65,12 @@ The Diabetes Care perspective provides a specific mechanism example: produce pre Amodei's complementary factors framework explicitly identifies 'human constraints' (behavior change, social systems, meaning-making) as a factor that bounds AI returns even in biological science. This provides theoretical grounding for why the 80-90% non-clinical determinants remain unaddressed by AI-accelerated biology—they fall into the 'human constraints' category that AI cannot optimize. + +### Additional Evidence (extend) +*Source: [[2025-01-01-produce-prescriptions-diabetes-care-critique]] | Added: 2026-03-19* + +The produce prescription evidence gap illustrates the mechanism: knowing that social factors (food quality) drive health outcomes doesn't automatically mean that interventions targeting those factors (food vouchers) improve health. Food insecurity may be a proxy for poverty/stress/disadvantage rather than a direct causal factor. The ADA perspective shows that even when the correlation between social factors and health is proven, the causal pathway for interventions remains uncertain—food provision may improve food security without improving clinical outcomes if the underlying social determinants remain unaddressed. + --- ### Additional Evidence (confirm) diff --git a/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md b/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md index 109be2c38..ce955afd1 100644 --- a/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md +++ b/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md @@ -7,13 +7,17 @@ date: 2025-01-01 domain: health secondary_domains: [] format: perspective -status: unprocessed +status: enrichment priority: medium tags: [produce-prescriptions, food-is-medicine, diabetes, evidence-critique, causal-inference, intervention-design] processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md"] extraction_model: "anthropic/claude-sonnet-4.5" +processed_by: vida +processed_date: 2026-03-19 +enrichments_applied: ["SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -73,3 +77,10 @@ EXTRACTION HINT: The distinction between "food matters for health" (proven) and - Observational evaluations of produce prescriptions include multisite 9-program studies and Recipe4Health - Produce prescription programs showing HbA1c improvements typically enroll patients with baseline HbA1c >9% - The American Diabetes Association's journal is questioning the evidence standard for produce prescriptions + + +## Key Facts +- Diabetes Care published 'Food Is Medicine, but Are Produce Prescriptions?' perspective in 2023 +- Observational produce prescription evaluations include multisite 9-program studies and Recipe4Health +- Programs showing HbA1c improvements typically enroll patients with baseline HbA1c >9% +- The American Diabetes Association is the publisher of Diabetes Care journal diff --git a/inbox/queue/.extraction-debug/2025-01-01-produce-prescriptions-diabetes-care-critique.json b/inbox/queue/.extraction-debug/2025-01-01-produce-prescriptions-diabetes-care-critique.json index 55df92849..ff7ef3cea 100644 --- a/inbox/queue/.extraction-debug/2025-01-01-produce-prescriptions-diabetes-care-critique.json +++ b/inbox/queue/.extraction-debug/2025-01-01-produce-prescriptions-diabetes-care-critique.json @@ -1,7 +1,7 @@ { "rejected_claims": [ { - "filename": "produce-prescriptions-may-improve-food-security-without-clinical-outcomes-because-food-insecurity-proxies-poverty.md", + "filename": "produce-prescriptions-may-improve-food-security-without-clinical-outcomes-because-food-insecurity-proxies-for-poverty.md", "issues": [ "missing_attribution_extractor" ] @@ -10,15 +10,17 @@ "validation_stats": { "total": 1, "kept": 0, - "fixed": 1, + "fixed": 3, "rejected": 1, "fixes_applied": [ - "produce-prescriptions-may-improve-food-security-without-clinical-outcomes-because-food-insecurity-proxies-poverty.md:set_created:2026-03-18" + "produce-prescriptions-may-improve-food-security-without-clinical-outcomes-because-food-insecurity-proxies-for-poverty.md:set_created:2026-03-19", + "produce-prescriptions-may-improve-food-security-without-clinical-outcomes-because-food-insecurity-proxies-for-poverty.md:stripped_wiki_link:medical care explains only 10-20 percent of health outcomes ", + "produce-prescriptions-may-improve-food-security-without-clinical-outcomes-because-food-insecurity-proxies-for-poverty.md:stripped_wiki_link:SDOH interventions show strong ROI but adoption stalls becau" ], "rejections": [ - "produce-prescriptions-may-improve-food-security-without-clinical-outcomes-because-food-insecurity-proxies-poverty.md:missing_attribution_extractor" + "produce-prescriptions-may-improve-food-security-without-clinical-outcomes-because-food-insecurity-proxies-for-poverty.md:missing_attribution_extractor" ] }, "model": "anthropic/claude-sonnet-4.5", - "date": "2026-03-18" + "date": "2026-03-19" } \ No newline at end of file -- 2.45.2 From 1cd49663c8ae00d93142bcbb497e463a43098c28 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Thu, 19 Mar 2026 15:57:56 +0000 Subject: [PATCH 2/6] extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...ue is immediate unambiguous and low-risk.md | 6 ++++++ ... of US physicians daily within two years.md | 4 ++-- ...percent of deals are flat or down rounds.md | 6 ++++++ ...diagnostic accuracy in randomized trials.md | 6 ++++++ ...vidence-clinical-ai-growth-12b-valuation.md | 18 +++++++++++++++++- 5 files changed, 37 insertions(+), 3 deletions(-) diff --git a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md index 0084d2cf1..4b44f1ef4 100644 --- a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md +++ b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md @@ -55,6 +55,12 @@ WVU Medicine expanded Abridge ambient AI across 25 hospitals including rural fac Epic's AI Charting launch (Feb 2026) threatens to commoditize the ambient documentation beachhead that standalone AI companies used to establish clinical trust. Epic's 42% acute hospital market share and native EHR integration create 'good enough' dynamics where technical superiority matters less than bundled convenience. Early pilots show Epic comparable on simple notes but behind on complex specialties, suggesting the high-adoption documentation use case is splitting into commodity (Epic-captured) and premium (specialty-focused) segments. This challenges the interpretation that scribe adoption = sustainable moat—the beachhead may be rapidly commoditized by platform incumbents. + +### Additional Evidence (extend) +*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19* + +OpenEvidence represents a distinct clinical AI category from ambient scribes: clinical reasoning/decision support rather than documentation automation. While scribes (like Abridge) reached 92% adoption for documentation, OpenEvidence reached 40%+ daily physician usage for clinical reasoning at point of care. This suggests two parallel clinical AI beachheads: (1) documentation automation (ambient scribes), and (2) clinical reasoning support (OpenEvidence). The 44% physician concern rate about accuracy/misinformation despite heavy use indicates clinical reasoning AI faces persistent trust barriers that documentation AI does not. + --- Relevant Notes: diff --git a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md index 8043e9133..11a6793a0 100644 --- a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md +++ b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md @@ -25,9 +25,9 @@ OpenEvidence scale as of January 2026: 20M clinical consultations/month (up from ### Additional Evidence (extend) -*Source: [[2026-03-20-openevidence-1m-daily-consultations-milestone]] | Added: 2026-03-20* +*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19* -OpenEvidence reached 1 million clinical consultations in a single 24-hour period on March 10, 2026, representing a 30M+/month run rate—50% above their previous 20M/month benchmark. CEO Daniel Nadler claims 'OpenEvidence is used by more American doctors than all other AIs in the world—combined.' Institutional adoption expanded with Sutter Health collaboration to integrate OE into physician workflows. +OpenEvidence reached 20M clinical consultations/month by January 2026 (up from 8.5M in 2025, representing 2,000%+ YoY growth). On March 10, 2026, OpenEvidence became the first AI system to reach 1M clinical consultations in a single day. The platform is now used across 10,000+ hospitals and medical centers nationwide. Valuation tripled from $3.5B to $12B in under 12 months, with a $250M Series D led by Thrive Capital and DST Global in January 2026. --- diff --git a/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md b/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md index 27dfe5326..bd8c2f865 100644 --- a/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md +++ b/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md @@ -31,6 +31,12 @@ Abridge raised $300M Series E at $5B valuation and Ambiance raised $243M Series OpenEvidence valuation trajectory demonstrates winner-take-most dynamics: $3.5B → $6B → $12B in under 12 months, with $250M Series D led by Thrive Capital and DST Global. This 3.4x valuation increase in months while 35% of healthcare AI deals are flat/down rounds confirms capital concentration in category leaders. + +### Additional Evidence (confirm) +*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19* + +OpenEvidence valuation trajectory demonstrates extreme winner-take-most dynamics: $3.5B → $6B → $12B in under 12 months, with a $250M Series D in January 2026. This represents the fastest capital absorption in clinical AI history, with valuation tripling while the broader market shows 35% of deals at flat or down rounds. OpenEvidence is capturing category-defining capital velocity in clinical reasoning AI, separate from the ambient scribe market. + --- ### Additional Evidence (confirm) diff --git a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md index 9265e6e55..ca8dbd47a 100644 --- a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md +++ b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md @@ -23,6 +23,12 @@ The implication for AI deployment strategy: the highest-value clinical AI applic OpenEvidence achieved 100% USMLE score (first AI in history) and is now deployed at 20M consultations/month across 40%+ of US physicians, creating the first large-scale empirical test of whether benchmark performance translates to population health outcomes. The absence of published outcomes data at this deployment scale represents a critical evidence gap—if benchmark performance doesn't translate to clinical impact, we should see evidence of that at 20M monthly consultations. + +### Additional Evidence (challenge) +*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19* + +OpenEvidence became the first AI in history to score 100% on all parts of the USMLE, exceeding any human score on the most challenging medical licensing exam. This creates an empirical test case: OpenEvidence is now deployed at scale (20M consultations/month, 40%+ of US physicians daily) with perfect benchmark performance, yet no peer-reviewed outcomes data demonstrates whether this translates to improved patient outcomes. The absence of outcomes data at this scale represents a critical gap in validating whether benchmark performance predicts clinical impact. + --- ### Additional Evidence (confirm) diff --git a/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md b/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md index 7f239e7b3..b9c1d0fd0 100644 --- a/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md +++ b/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md @@ -7,13 +7,17 @@ date: 2026-01-01 domain: health secondary_domains: [ai-alignment] format: company-announcement -status: unprocessed +status: enrichment priority: medium tags: [openevidence, clinical-ai, decision-support, physician-adoption, clinical-decision-support, health-ai, trust] processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md"] extraction_model: "anthropic/claude-sonnet-4.5" +processed_by: vida +processed_date: 2026-03-19 +enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md", "AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -74,6 +78,18 @@ WHY ARCHIVED: Significant scale update — the existing claim understates 2026 m EXTRACTION HINT: Update the existing claim with scale metrics, but flag the benchmark-to-outcomes translation tension as a challenge to both the OpenEvidence claim and the benchmark performance claim +## Key Facts +- OpenEvidence reached 8.5M clinical consultations/month in 2025 +- OpenEvidence reached 20M clinical consultations/month by January 2026 +- OpenEvidence valuation: $3.5B → $6B → $12B in under 12 months +- OpenEvidence Series D: $250M led by Thrive Capital and DST Global (January 2026) +- OpenEvidence first AI to score 100% on USMLE (all parts) +- OpenEvidence used across 10,000+ hospitals and medical centers +- March 10, 2026: OpenEvidence reached 1M consultations in one day +- 44% of physicians concerned about OpenEvidence accuracy/misinformation risk +- 19% of physicians concerned about lack of physician oversight/explainability + + ## Key Facts - OpenEvidence reached 8.5M clinical consultations/month in 2025 - OpenEvidence reached 20M clinical consultations/month by January 2026 -- 2.45.2 From 4c34b2f678eeb147ad2d44bc29f6058eefa91da1 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Thu, 19 Mar 2026 16:02:19 +0000 Subject: [PATCH 3/6] extract: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...alue is immediate unambiguous and low-risk.md | 6 +++--- ...ng constraint between headcount and output.md | 6 ++++++ ...-charting-ambient-scribe-market-disruption.md | 16 +++++++++++++++- ...harting-ambient-scribe-market-disruption.json | 8 ++++---- 4 files changed, 28 insertions(+), 8 deletions(-) diff --git a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md index 4b44f1ef4..1ea235334 100644 --- a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md +++ b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md @@ -56,10 +56,10 @@ WVU Medicine expanded Abridge ambient AI across 25 hospitals including rural fac Epic's AI Charting launch (Feb 2026) threatens to commoditize the ambient documentation beachhead that standalone AI companies used to establish clinical trust. Epic's 42% acute hospital market share and native EHR integration create 'good enough' dynamics where technical superiority matters less than bundled convenience. Early pilots show Epic comparable on simple notes but behind on complex specialties, suggesting the high-adoption documentation use case is splitting into commodity (Epic-captured) and premium (specialty-focused) segments. This challenges the interpretation that scribe adoption = sustainable moat—the beachhead may be rapidly commoditized by platform incumbents. -### Additional Evidence (extend) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19* +### Additional Evidence (challenge) +*Source: [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] | Added: 2026-03-19* -OpenEvidence represents a distinct clinical AI category from ambient scribes: clinical reasoning/decision support rather than documentation automation. While scribes (like Abridge) reached 92% adoption for documentation, OpenEvidence reached 40%+ daily physician usage for clinical reasoning at point of care. This suggests two parallel clinical AI beachheads: (1) documentation automation (ambient scribes), and (2) clinical reasoning support (OpenEvidence). The 44% physician concern rate about accuracy/misinformation despite heavy use indicates clinical reasoning AI faces persistent trust barriers that documentation AI does not. +Epic's February 2026 AI Charting launch threatens to commoditize the documentation beachhead. While AI scribes achieved 92% provider adoption, Epic's native integration advantage (full patient history access, single-vendor IT preference, add-on pricing vs. millions in standalone contracts) means the 'easy adoption' use case may not translate to sustainable competitive moats. Abridge CEO Shiv Rao is repositioning the company as 'more than an AI scribe' by pursuing prior authorization and clinical decision support, suggesting the documentation-only market is now contested. The high adoption rate may have been a function of being first to an undefended use case rather than a durable advantage. --- diff --git a/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md b/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md index 650644927..ce3418894 100644 --- a/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md +++ b/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md @@ -44,6 +44,12 @@ BVP reports AI-native healthcare companies achieve $500K-$1M+ ARR per FTE with 7 Abridge's productivity premium may not survive platform commoditization. Despite being KLAS #1 ambient scribe with 150+ health system deployments, Epic's native AI Charting threatens Abridge's core documentation revenue through integration advantages and 'good enough' quality at lower switching costs. Abridge is repositioning toward clinical decision support and prior authorization—higher-value use cases Epic hasn't matched—suggesting the productivity premium only holds when the AI company can stay ahead of platform commoditization cycles. + +### Additional Evidence (challenge) +*Source: [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] | Added: 2026-03-19* + +Epic's platform commoditization of AI scribes suggests the productivity premium may not survive when incumbents add 'good enough' AI to existing workflows. Abridge's 150+ health system deployments and best-in-class accuracy face pressure from Epic's native integration, which doesn't require matching quality—just being sufficient for most documentation use cases. If platform incumbents can capture high-volume segments with lower-quality but better-integrated AI, the revenue productivity advantage may only persist in high-complexity niches where integration advantages don't overcome the quality gap. + --- Relevant Notes: diff --git a/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md b/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md index 2d61c18d0..3b9fa497b 100644 --- a/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md +++ b/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md @@ -7,7 +7,7 @@ date: 2026-02-04 domain: health secondary_domains: [ai-alignment] format: news -status: unprocessed +status: enrichment priority: high tags: [epic, ai-scribe, ambient-documentation, clinical-ai, abridge, microsoft, market-dynamics, ehr] flagged_for_theseus: ["Epic's AI Charting is a platform entrenchment move — the clinical AI safety question is whether EHR-native AI has different oversight properties than external tools"] @@ -15,6 +15,10 @@ processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md", "AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md"] extraction_model: "anthropic/claude-sonnet-4.5" +processed_by: vida +processed_date: 2026-03-19 +enrichments_applied: ["AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md", "AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -79,3 +83,13 @@ EXTRACTION HINT: The "good enough" dynamic is the key claim — extract that as - Epic AI Charting announced February 4, 2026 - Early Epic AI Charting pilots show comparable performance on simple note types, significantly behind on complex specialties - Standalone scribe contracts can reach millions annually for health systems + + +## Key Facts +- Epic Systems controls 42% of acute hospital EHR market share as of Feb 2026 +- Epic covers 55% of US hospital beds +- Abridge won top ambient scribe slot in 2025 KLAS annual report +- Abridge has 150+ health system deployments as of Feb 2026 +- Ambient scribe market estimated at $2B +- Standalone AI scribe contracts can reach millions annually for health systems +- Early Epic AI Charting pilots show comparable performance on simple note types, significantly behind on complex specialties diff --git a/inbox/queue/.extraction-debug/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.json b/inbox/queue/.extraction-debug/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.json index 12047c07c..a5190f5fb 100644 --- a/inbox/queue/.extraction-debug/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.json +++ b/inbox/queue/.extraction-debug/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.json @@ -1,7 +1,7 @@ { "rejected_claims": [ { - "filename": "ehr-native-ai-commoditizes-ambient-documentation-through-good-enough-integration-forcing-standalone-scribes-to-differentiate-on-clinical-decision-support.md", + "filename": "platform-incumbents-commoditize-beachhead-use-cases-through-good-enough-native-integration-forcing-startups-to-differentiate-on-complexity-not-quality.md", "issues": [ "missing_attribution_extractor" ] @@ -13,12 +13,12 @@ "fixed": 1, "rejected": 1, "fixes_applied": [ - "ehr-native-ai-commoditizes-ambient-documentation-through-good-enough-integration-forcing-standalone-scribes-to-differentiate-on-clinical-decision-support.md:set_created:2026-03-18" + "platform-incumbents-commoditize-beachhead-use-cases-through-good-enough-native-integration-forcing-startups-to-differentiate-on-complexity-not-quality.md:set_created:2026-03-19" ], "rejections": [ - "ehr-native-ai-commoditizes-ambient-documentation-through-good-enough-integration-forcing-standalone-scribes-to-differentiate-on-clinical-decision-support.md:missing_attribution_extractor" + "platform-incumbents-commoditize-beachhead-use-cases-through-good-enough-native-integration-forcing-startups-to-differentiate-on-complexity-not-quality.md:missing_attribution_extractor" ] }, "model": "anthropic/claude-sonnet-4.5", - "date": "2026-03-18" + "date": "2026-03-19" } \ No newline at end of file -- 2.45.2 From e963e3ada9762c4e55c73f9cca1dd6f11ebb018f Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Thu, 19 Mar 2026 16:08:29 +0000 Subject: [PATCH 4/6] extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...the net cost impact inflationary through 2035.md | 12 +++--------- ...ty-patients-undermining-chronic-use-economics.md | 4 ++-- ...style-modification-efficacy-combined-approach.md | 13 +++++++++++++ 3 files changed, 18 insertions(+), 11 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index f0d0b2fdc..18234a658 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -115,21 +115,15 @@ International generic competition beginning January 2026 (Canada patent expiry, ### Additional Evidence (challenge) -*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19* +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy. ### Additional Evidence (challenge) -*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19* +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* -Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded and time-limited: costs rise 23% vs 10% in year 1, but after 12 months medical costs grow just 2% vs 6% for non-users. At 30 months for diabetes patients, medical cost growth is 6-9 percentage points lower. This suggests the 'inflationary through 2035' claim may be true only for short-term payers who never capture the year-2+ savings, while long-term risk-bearers see net cost reduction. The inflationary impact depends on payment model structure, not just the chronic use model itself. - - -### Additional Evidence (challenge) -*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20* - -India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033. +If GLP-1 + exercise combination creates durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone) that persists after discontinuation, the chronic use economic model may be unnecessarily pessimistic. Value could accrue from shorter medication courses paired with intensive behavioral support, reducing long-term pharmaceutical spend while maintaining clinical benefits. --- diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 596ebca7e..19fe52b72 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -97,7 +97,7 @@ GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacol ### Additional Evidence (extend) -*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19* +*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise reduces regain to 3.5 kg. This suggests the low persistence rates may be economically rational from a patient perspective if medication alone provides no durable benefit—patients who discontinue without establishing exercise habits return to baseline regardless of medication duration. @@ -105,7 +105,7 @@ Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than pla ### Additional Evidence (extend) *Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19* -Aon data shows benefits scale dramatically with adherence: for diabetes patients, medical cost growth is 6 percentage points lower at 30 months overall, but 9 points lower with 80%+ adherence. For weight loss patients, cost growth is 3 points lower at 18 months overall, but 7 points lower with consistent use. Adherent users (80%+) show 47% fewer MACE hospitalizations for women and 26% for men. This confirms that adherence is the binding variable—the 80%+ adherent cohort shows the strongest effects across all outcomes, making low persistence rates even more economically damaging. +Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise (3.5 kg regain) maintains 60% more weight loss. This suggests the adherence paradox may be misframed—the economic value may not require chronic medication use if behavioral interventions create durable change that outlasts pharmacotherapy. --- diff --git a/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md b/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md index b0e625d2b..d068c7334 100644 --- a/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md +++ b/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md @@ -18,6 +18,10 @@ processed_by: vida processed_date: 2026-03-19 enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] extraction_model: "anthropic/claude-sonnet-4.5" +processed_by: vida +processed_date: 2026-03-19 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -102,3 +106,12 @@ EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison - At week 52 all intervention groups regained weight after stopping; by week 104: placebo +7.6 kg, liraglutide only +8.7 kg, exercise only +5.4 kg, combination +3.5 kg - Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication) - ADA notes new therapies claiming 'enhanced quality of weight loss by improving muscle preservation' but no FDA-approved compounds with proven muscle preservation yet + + +## Key Facts +- Meta-analysis of 22 RCTs with 2,258 participants found approximately 25% of GLP-1 weight loss is lean mass +- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced +- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of interventions +- WHO December 2025 guidelines recommend GLP-1 therapies 'combined with intensive behavioral therapy' +- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary, not FDA-approved) +- Weight regain by week 104: placebo +7.6 kg, liraglutide only +8.7 kg, exercise only +5.4 kg, combination +3.5 kg -- 2.45.2 From 4f00ed7cc6be14352b3e5d345e268f194b872c58 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Tue, 24 Mar 2026 14:41:35 +0000 Subject: [PATCH 5/6] auto-fix: strip 32 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...AI value is immediate unambiguous and low-risk.md | 8 ++++---- ...caling constraint between headcount and output.md | 4 ++-- ... the net cost impact inflationary through 2035.md | 6 +++--- ...ercent of US physicians daily within two years.md | 8 ++++---- ...al infrastructure connects screening to action.md | 8 ++++---- ...ity-patients-undermining-chronic-use-economics.md | 2 +- ...le 35 percent of deals are flat or down rounds.md | 4 ++-- ...milar diagnostic accuracy in randomized trials.md | 8 ++++---- ...nate as four independent methodologies confirm.md | 12 ++++++------ ...-openevidence-clinical-ai-growth-12b-valuation.md | 2 +- ...c-ai-charting-ambient-scribe-market-disruption.md | 2 +- 11 files changed, 32 insertions(+), 32 deletions(-) diff --git a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md index 1ea235334..45e141c32 100644 --- a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md +++ b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md @@ -27,25 +27,25 @@ The contrast is instructive: since [[medical LLM benchmark performance does not ### Additional Evidence (extend) -*Source: [[2025-06-01-abridge-valuation-growth-ai-scribe-metrics]] | Added: 2026-03-16* +*Source: 2025-06-01-abridge-valuation-growth-ai-scribe-metrics | Added: 2026-03-16* Abridge's clinical outcomes data shows 73% reduction in after-hours documentation time, 61% reduction in cognitive burden, and 81% improvement in workflow satisfaction. The company won top ambient AI slot in 2025 KLAS annual report and deployed across 150+ health systems including Kaiser (24,600 physicians), Mayo Clinic (2,000+ physicians enterprise-wide), Johns Hopkins, Duke, UPMC, and Yale New Haven. This represents the transition from pilot adoption to enterprise-wide deployment at scale. ### Additional Evidence (challenge) -*Source: [[2025-06-01-abridge-valuation-growth-ai-scribe-metrics]] | Added: 2026-03-16* +*Source: 2025-06-01-abridge-valuation-growth-ai-scribe-metrics | Added: 2026-03-16* Epic launched AI Charting in February 2026, creating an immediate commoditization threat to standalone ambient AI platforms. Abridge's response - pivoting to 'more than a scribe' positioning with coding, prior auth automation, and clinical decision support - suggests leadership recognized the documentation beachhead may not be defensible against EHR-native solutions. The timing of this strategic pivot (2025-2026) indicates the scribe adoption success may have a shorter durability window than the 92% adoption figure suggests. ### Additional Evidence (challenge) -*Source: [[2026-01-01-bvp-state-of-health-ai-2026]] | Added: 2026-03-16* +*Source: 2026-01-01-bvp-state-of-health-ai-2026 | Added: 2026-03-16* The 92% figure applies to 'deploying, implementing, or piloting' ambient AI as of March 2025, not active deployment. This includes very early-stage pilots. The scope distinction between pilot programs and daily clinical workflow integration is significant — the claim may overstate actual adoption if interpreted as active use rather than organizational commitment to explore the technology. ### Additional Evidence (extend) -*Source: [[2026-03-11-wvu-abridge-rural-health-systems-expansion]] | Added: 2026-03-16* +*Source: 2026-03-11-wvu-abridge-rural-health-systems-expansion | Added: 2026-03-16* WVU Medicine expanded Abridge ambient AI across 25 hospitals including rural facilities in March 2026, one month after Epic AI Charting launch. This rural expansion suggests ambient AI has passed from pilot phase to broad deployment phase, as enterprise technology typically enters academic medical centers first, then regional health systems, then rural/critical access hospitals last. The fact that a state academic health system serving one of the most rural and medically underserved states chose to expand Abridge post-Epic launch provides implicit market validation of Abridge's competitive position. diff --git a/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md b/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md index ce3418894..2d87913d0 100644 --- a/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md +++ b/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md @@ -28,13 +28,13 @@ Since [[healthcares defensible layer is where atoms become bits because physical ### Additional Evidence (confirm) -*Source: [[2025-06-01-abridge-valuation-growth-ai-scribe-metrics]] | Added: 2026-03-16* +*Source: 2025-06-01-abridge-valuation-growth-ai-scribe-metrics | Added: 2026-03-16* Abridge reached $100M ARR with 150+ health system customers by May 2025, achieving $5.3B valuation. This represents the clearest real-world validation of AI-native productivity claims in healthcare - a documentation platform scaling to 9-figure revenue without the linear headcount scaling that would be required for traditional medical transcription or documentation services. ### Additional Evidence (confirm) -*Source: [[2026-01-01-bvp-state-of-health-ai-2026]] | Added: 2026-03-16* +*Source: 2026-01-01-bvp-state-of-health-ai-2026 | Added: 2026-03-16* BVP reports AI-native healthcare companies achieve $500K-$1M+ ARR per FTE with 70-80%+ software-like margins, compared to $100-200K for traditional healthcare services and $200-400K for pre-AI healthcare SaaS. This is the primary source for the productivity claim, providing the specific ranges that support the 3-5x multiplier. diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 18234a658..3c392007c 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -128,17 +128,17 @@ If GLP-1 + exercise combination creates durable weight maintenance (3.5 kg regai --- ### Additional Evidence (challenge) -*Source: [[2026-03-21-natco-semaglutide-india-day1-launch-1290]] | Added: 2026-03-21* +*Source: 2026-03-21-natco-semaglutide-india-day1-launch-1290 | Added: 2026-03-21* Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on March 20, 2026, the day the patent expired. This is 90% below innovator pricing and 2-3x lower than analyst projections made days earlier ($40-77/month within a year). 50+ manufacturers from 40+ companies are entering the market, with Sun Pharma, Zydus, Dr. Reddy's, and Eris launching on Day 1. The 'inflationary through 2035' timeline is empirically wrong for international markets—price compression is happening in 2026, not 2030+. ### Additional Evidence (extend) -*Source: [[2026-03-21-semaglutide-us-import-wall-gray-market-pressure]] | Added: 2026-03-21* +*Source: 2026-03-21-semaglutide-us-import-wall-gray-market-pressure | Added: 2026-03-21* US patent protection extends to 2031-2033 for Ozempic and Wegovy, creating a legal wall that prevents approved generic competition until then. The compounding pharmacy channel that provided affordable access during 2023-2025 closed in February 2025 when FDA removed semaglutide from the shortage list. This means the US will remain 'inflationary' through legal channels through 2031-2033, but gray market pressure from $15/month Indian generics versus $1,200/month Wegovy will create illegal importation at scale. ### Additional Evidence (challenge) -*Source: [[2026-03-22-health-canada-rejects-dr-reddys-semaglutide]] | Added: 2026-03-22* +*Source: 2026-03-22-health-canada-rejects-dr-reddys-semaglutide | Added: 2026-03-22* Health Canada rejected Dr. Reddy's generic semaglutide application in October 2025, delaying Canada launch to 2027 at earliest (8-12 month review cycle after resubmission). This contradicts the Session 9 projection of May 2026 Canada launch and reveals regulatory friction as a significant barrier to generic GLP-1 market entry. Canada's patents expired January 2026, but regulatory approval does not automatically follow patent expiration. The delay removes the primary high-income market data point for 2026, leaving only India's $15-55/month pricing as the sole confirmed generic market reference. Canada was expected to establish pricing floors for high-income markets with US-comparable health infrastructure, but that calibration point is now delayed 12+ months beyond patent cliff. diff --git a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md index 11a6793a0..a9b681e52 100644 --- a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md +++ b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md @@ -32,22 +32,22 @@ OpenEvidence reached 20M clinical consultations/month by January 2026 (up from 8 --- ### Additional Evidence (extend) -*Source: [[2026-03-21-openevidence-12b-valuation-nct07199231-outcomes-gap]] | Added: 2026-03-21* +*Source: 2026-03-21-openevidence-12b-valuation-nct07199231-outcomes-gap | Added: 2026-03-21* OpenEvidence reached 30M+ monthly consultations by March 2026, including a historic milestone of 1 million consultations in a single day on March 10, 2026. The company projects 'more than 100 million Americans will be treated by a clinician using OpenEvidence this year.' This represents continued exponential growth from the 18M monthly consultations reported in December 2025. ### Additional Evidence (challenge) -*Source: [[2026-03-22-arise-state-of-clinical-ai-2026]] | Added: 2026-03-22* +*Source: 2026-03-22-arise-state-of-clinical-ai-2026 | Added: 2026-03-22* ARISE report reframes OpenEvidence adoption as shadow-IT workaround behavior rather than validation of clinical value. Clinicians use OE to 'bypass slow internal IT systems' because institutional tools are too slow for clinical workflows. This suggests rapid adoption reflects institutional system failure, not OE's clinical superiority. ### Additional Evidence (extend) -*Source: [[2026-03-22-openevidence-sutter-health-epic-integration]] | Added: 2026-03-22* +*Source: 2026-03-22-openevidence-sutter-health-epic-integration | Added: 2026-03-22* Sutter Health (3.3M patients, ~12,000 physicians) integrated OpenEvidence into Epic EHR workflows in February 2026, marking the first major health-system-wide EHR embedding. This shifts OpenEvidence from standalone app to in-workflow clinical tool, institutionalizing what ARISE identified as physicians bypassing institutional IT governance. ### Additional Evidence (extend) -*Source: [[2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review]] | Added: 2026-03-24* +*Source: 2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review | Added: 2026-03-24* iatroX reports OE has 'signalled plans for global expansion as a key 2026 and beyond initiative' with UK, Canada, Australia identified as 'English-first markets with lower regulatory barriers.' However, iatroX notes this perception may be inaccurate for UK: NHS requires DTAC + MHRA Class 1 for formal deployment. OE's characterization of UK as having 'lower regulatory barriers' relative to US may be a strategic misjudgment—UK NHS has MORE formal digital health procurement governance than US (no federal equivalent to DTAC). diff --git a/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md b/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md index 3d88f6335..522304e92 100644 --- a/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md +++ b/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md @@ -19,25 +19,25 @@ The near-term trajectory: mandatory outpatient screening by 2026, Z-code adoptio ### Additional Evidence (extend) -*Source: [[2024-09-19-commonwealth-fund-mirror-mirror-2024]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5* +*Source: 2024-09-19-commonwealth-fund-mirror-mirror-2024 | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5* The Commonwealth Fund's 2024 international comparison provides quantified evidence of the population-level cost of not operationalizing SDOH interventions at scale. The US ranks second-worst on equity (9th of 10 countries) and last on health outcomes (10th of 10), with the highest healthcare spending (>16% of GDP). This outcome gap relative to peer nations with lower spending demonstrates the opportunity cost of the US healthcare system's failure to systematically address social determinants. Countries with better equity and access outcomes (Australia, Netherlands) achieve superior population health despite similar or lower clinical quality and lower spending ratios. The international comparison quantifies what the SDOH adoption gap costs: the US achieves worst population health outcomes among wealthy peer nations despite world-class clinical care, suggesting that the 3% Z-code documentation rate represents billions in foregone health gains. ### Additional Evidence (challenge) -*Source: [[2025-04-07-tufts-health-affairs-medically-tailored-meals-50-states]] | Added: 2026-03-18* +*Source: 2025-04-07-tufts-health-affairs-medically-tailored-meals-50-states | Added: 2026-03-18* The JAMA Internal Medicine 2024 RCT testing intensive food-as-medicine intervention (10 meals/week + education + coaching for 1 year) found NO significant difference in HbA1c, hospitalization, ED use, or total claims between treatment and control groups. This challenges the assumption that SDOH interventions produce strong ROI—the RCT evidence shows null clinical outcomes despite addressing food insecurity directly. ### Additional Evidence (extend) -*Source: [[2025-09-01-lancet-public-health-social-prescribing-england-national-rollout]] | Added: 2026-03-18* +*Source: 2025-09-01-lancet-public-health-social-prescribing-england-national-rollout | Added: 2026-03-18* England's social prescribing provides international counterpoint: 1.3M annual referrals with 3,300 link workers represents the operational infrastructure that US SDOH interventions lack. However, UK achieved scale without evidence quality - 15 of 17 economic studies were uncontrolled, 38% attrition, SROI ratios of £1.17-£7.08 but ROI only 0.11-0.43. This suggests infrastructure alone is insufficient without measurement systems. ### Additional Evidence (extend) -*Source: [[2025-01-01-nashp-chw-state-policies-2024-2025]] | Added: 2026-03-18* +*Source: 2025-01-01-nashp-chw-state-policies-2024-2025 | Added: 2026-03-18* Community health worker programs demonstrate the same payment boundary stall: only 20 states have Medicaid State Plan Amendments for CHW reimbursement 17 years after Minnesota's 2008 approval, despite 39 RCTs showing $2.47 ROI. The billing infrastructure bottleneck is identical to Z-code documentation failure — SPAs typically use 9896x CPT codes but uptake remains slow because community-based organizations lack contracting infrastructure and Medicaid does not cover provider travel costs (the largest CHW overhead expense). 7 states have established dedicated CHW offices and 6 enacted new reimbursement legislation in 2024-2025, but the gap between evidence (strong) and operational infrastructure (absent) mirrors the SDOH screening-to-action gap. diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 19fe52b72..a59269ef9 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -115,7 +115,7 @@ Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than pla Novo Nordisk's response to India's generic launch reveals market expansion strategy: only 200,000 of 250 million obese Indians are currently on GLP-1s. The company is competing on 'market expansion over price war,' suggesting the primary barrier is access/awareness, not price sensitivity. This implies persistence challenges may be access-driven in international markets rather than purely adherence-driven. ### Additional Evidence (extend) -*Source: [[2025-04-01-jmir-glp1-digital-engagement-outcomes-retrospective]] | Added: 2026-03-24* +*Source: 2025-04-01-jmir-glp1-digital-engagement-outcomes-retrospective | Added: 2026-03-24* US real-world data from JMIR 2025 shows digital engagement produces 11.53% weight loss vs. 8% for non-engaged participants at month 5 (3.5pp advantage). Study covers both semaglutide and tirzepatide, demonstrating the behavioral support effect generalizes across GLP-1/GIP receptor agonists. When supply and coverage issues are addressed, persistence improves to 63%, suggesting the adherence gap is partially addressable through digital platform integration (live coaching, monitoring, education). diff --git a/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md b/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md index bd8c2f865..f829c9673 100644 --- a/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md +++ b/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md @@ -21,7 +21,7 @@ The emerging consensus: healthcare AI is a platform shift, not a bubble, but the ### Additional Evidence (confirm) -*Source: [[2026-01-01-bvp-state-of-health-ai-2026]] | Added: 2026-03-16* +*Source: 2026-01-01-bvp-state-of-health-ai-2026 | Added: 2026-03-16* Abridge raised $300M Series E at $5B valuation and Ambiance raised $243M Series C at $1.04B valuation by early 2026, demonstrating the capital concentration in category leaders. Function Health's $300M Series C at $2.2B valuation further confirms winner-take-most dynamics in health AI. @@ -40,7 +40,7 @@ OpenEvidence valuation trajectory demonstrates extreme winner-take-most dynamics --- ### Additional Evidence (confirm) -*Source: [[2026-03-21-openevidence-12b-valuation-nct07199231-outcomes-gap]] | Added: 2026-03-21* +*Source: 2026-03-21-openevidence-12b-valuation-nct07199231-outcomes-gap | Added: 2026-03-21* OpenEvidence raised $250M at $12B valuation in January 2026, representing a 3.4x valuation increase in approximately 3 months (from $3.5B in October 2025). This is extraordinary velocity even by AI standards, with the company achieving $150M ARR (1,803% YoY growth from $7.9M in 2024) at ~90% gross margins. The winner-take-most pattern is evident as OE captures the clinical AI category. diff --git a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md index ca8dbd47a..0e61caa9b 100644 --- a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md +++ b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md @@ -32,22 +32,22 @@ OpenEvidence became the first AI in history to score 100% on all parts of the US --- ### Additional Evidence (confirm) -*Source: [[2026-03-21-openevidence-12b-valuation-nct07199231-outcomes-gap]] | Added: 2026-03-21* +*Source: 2026-03-21-openevidence-12b-valuation-nct07199231-outcomes-gap | Added: 2026-03-21* OpenEvidence's medRxiv preprint (November 2025) showed 24% accuracy for relevant answers on complex open-ended clinical scenarios, despite achieving 100% on USMLE-type multiple choice questions. This 76-percentage-point gap between benchmark performance and open-ended clinical scenarios confirms that structured test performance does not predict real-world clinical utility. ### Additional Evidence (extend) -*Source: [[2026-03-22-arise-state-of-clinical-ai-2026]] | Added: 2026-03-22* +*Source: 2026-03-22-arise-state-of-clinical-ai-2026 | Added: 2026-03-22* ARISE report identifies specific failure modes: real-world performance 'breaks down when systems must manage uncertainty, incomplete information, or multi-step workflows.' This provides mechanistic detail for why benchmark performance doesn't translate — benchmarks test pattern recognition on complete data while clinical care requires uncertainty management. ### Additional Evidence (extend) -*Source: [[2025-11-01-jmir-knowledge-practice-gap-39-benchmarks-systematic-review]] | Added: 2026-03-24* +*Source: 2025-11-01-jmir-knowledge-practice-gap-39-benchmarks-systematic-review | Added: 2026-03-24* JMIR systematic review of 761 studies provides methodological foundation: 95% of clinical LLM evaluation uses medical exam questions rather than real patient data, with only 5% assessing performance on actual patient care. Traditional benchmarks show saturation at 84-90% USMLE accuracy, but conversational frameworks reveal 19.3pp accuracy drop (82% → 62.7%) when moving from case vignettes to multi-turn dialogues. Review concludes: 'substantial disconnects from clinical reality and foundational gaps in construct validity, data integrity, and safety coverage.' This establishes that the Oxford/Nature Medicine RCT deployment gap (94.9% → 34.5%) is part of a systematic field-wide pattern, not an isolated finding. ### Additional Evidence (extend) -*Source: [[2026-02-10-oxford-nature-medicine-llm-public-medical-advice-rct]] | Added: 2026-03-24* +*Source: 2026-02-10-oxford-nature-medicine-llm-public-medical-advice-rct | Added: 2026-03-24* Oxford Nature Medicine 2026 RCT (n=1,298) extends the benchmark-to-clinical-impact gap to public users: LLMs achieved 94.9% condition identification in isolation but users assisted by LLMs performed no better than control groups (<34.5%). The 60-point deployment gap held across GPT-4o, Llama 3, and Command R+, indicating the interaction mode—not the model—explains the failure. Root cause identified as 'two-way communication breakdown' where users couldn't extract correct guidance even when AI possessed the right answer. diff --git a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md index 9fdc650f6..14bc59c0f 100644 --- a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md +++ b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md @@ -31,25 +31,25 @@ This has structural implications for how healthcare should be organized. Since [ ### Additional Evidence (confirm) -*Source: [[2024-09-19-commonwealth-fund-mirror-mirror-2024]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5* +*Source: 2024-09-19-commonwealth-fund-mirror-mirror-2024 | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5* The Commonwealth Fund's 2024 Mirror Mirror international comparison provides the strongest real-world proof of this claim. The US ranks **second in care process quality** (clinical excellence when care is accessed) but **last in health outcomes** (life expectancy, avoidable deaths) among 10 peer nations. This paradox proves that clinical quality alone cannot produce population health — the US has near-best clinical care AND worst outcomes, demonstrating that non-clinical factors (access, equity, social determinants) dominate outcome determination. The care process vs. outcomes decoupling across 70 measures and nearly 75% patient/physician-reported data is the international benchmark showing medical care's limited contribution to population health outcomes. ### Additional Evidence (extend) -*Source: [[2025-00-00-nhs-england-waiting-times-underfunding]] | Added: 2026-03-15* +*Source: 2025-00-00-nhs-england-waiting-times-underfunding | Added: 2026-03-15* The NHS paradox—ranking 3rd overall while having catastrophic specialty access—provides supporting evidence that medical care's contribution to health outcomes is limited. A system can have multi-year waits for specialty procedures yet still rank highly in overall health system performance because primary care, equity, and universal coverage (which address behavioral and social factors) matter more than specialty delivery speed for population health outcomes. ### Additional Evidence (confirm) -*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16* +*Source: 2025-12-01-who-glp1-global-guidelines-obesity | Added: 2026-03-16* WHO's three-pillar framework for GLP-1 obesity treatment explicitly positions medication as one component within a comprehensive approach requiring healthy diets, physical activity, professional support, and population-level policies. WHO states obesity is a 'societal challenge requiring multisectoral action — not just individual medical treatment.' This institutional positioning from the global health authority confirms that pharmaceutical intervention alone cannot address health outcomes driven by behavioral and social factors. ### Additional Evidence (extend) -*Source: [[2025-04-07-tufts-health-affairs-medically-tailored-meals-50-states]] | Added: 2026-03-18* +*Source: 2025-04-07-tufts-health-affairs-medically-tailored-meals-50-states | Added: 2026-03-18* While social determinants predict health outcomes in observational studies, RCT evidence from food-as-medicine interventions shows that directly addressing social determinants (food insecurity) does not automatically improve clinical outcomes. The AHA 2025 systematic review of 14 US RCTs found Food Is Medicine programs improve diet quality and food security but "impact on clinical outcomes was inconsistent and often failed to reach statistical significance." This suggests the causal pathway from social determinants to health is more complex than simple resource provision. @@ -61,7 +61,7 @@ The Diabetes Care perspective provides a specific mechanism example: produce pre ### Additional Evidence (confirm) -*Source: [[2026-03-19-vida-ai-biology-acceleration-healthspan-constraint]] | Added: 2026-03-19* +*Source: 2026-03-19-vida-ai-biology-acceleration-healthspan-constraint | Added: 2026-03-19* Amodei's complementary factors framework explicitly identifies 'human constraints' (behavior change, social systems, meaning-making) as a factor that bounds AI returns even in biological science. This provides theoretical grounding for why the 80-90% non-clinical determinants remain unaddressed by AI-accelerated biology—they fall into the 'human constraints' category that AI cannot optimize. @@ -74,7 +74,7 @@ The produce prescription evidence gap illustrates the mechanism: knowing that so --- ### Additional Evidence (confirm) -*Source: [[2026-03-10-abrams-bramajo-pnas-birth-cohort-mortality-us-life-expectancy]] | Added: 2026-03-24* +*Source: 2026-03-10-abrams-bramajo-pnas-birth-cohort-mortality-us-life-expectancy | Added: 2026-03-24* PNAS 2026 attributes US life expectancy stagnation to 'a complex convergence of rising chronic disease, shifting behavioral risks, and increases in certain cancers among younger adults' — explicitly identifying behavioral and social factors as the drivers of cohort-level mortality deterioration, not medical care quality. diff --git a/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md b/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md index b9c1d0fd0..0bd1728dc 100644 --- a/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md +++ b/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md @@ -58,7 +58,7 @@ This creates a two-track clinical AI story: (1) Abridge/ambient scribes for docu **What surprised me:** The USMLE 100% score and the 1M consultations/day milestone suggest OpenEvidence is in a different category from early clinical AI tools. At 20M consultations/month with verified physicians, this is larger than any previously deployed clinical decision support system. -**What I expected but didn't find:** No peer-reviewed outcomes data on whether OpenEvidence-assisted consultations produce better patient outcomes. The benchmark performance (USMLE 100%) doesn't necessarily translate to clinical impact — existing KB claim [[medical LLM benchmark performance does not translate to clinical impact]] is a direct challenge to this data. +**What I expected but didn't find:** No peer-reviewed outcomes data on whether OpenEvidence-assisted consultations produce better patient outcomes. The benchmark performance (USMLE 100%) doesn't necessarily translate to clinical impact — existing KB claim medical LLM benchmark performance does not translate to clinical impact is a direct challenge to this data. **KB connections:** - Updates: [[OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years]] — the claim is still accurate but understates 2026 scale diff --git a/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md b/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md index 3b9fa497b..6c52d13de 100644 --- a/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md +++ b/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md @@ -61,7 +61,7 @@ Epic Systems announced its AI Charting feature on February 4, 2026 — a native **KB connections:** - Challenges the "beachhead" interpretation of: [[AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk]] - The Epic threat parallels the "Big Tech risk" in Belief 4 (atoms-to-bits boundary) — but applied to documentation software, not hardware. The moat (clinical trust, regulatory expertise) may not apply to documentation where Epic already has the trust. -- Connects to: [[AI-native health companies achieve 3-5x the revenue productivity of traditional health services]] — the question is whether that productivity premium survives platform commoditization +- Connects to: AI-native health companies achieve 3-5x the revenue productivity of traditional health services — the question is whether that productivity premium survives platform commoditization **Extraction hints:** - CLAIM CANDIDATE: "Epic's native AI Charting threatens to commoditize ambient documentation, forcing standalone AI scribe companies to differentiate on clinical decision support and workflow automation rather than note quality" -- 2.45.2 From 43adcd89d85fc820980714f56ba3ed0ad2b4e7c1 Mon Sep 17 00:00:00 2001 From: m3taversal Date: Tue, 24 Mar 2026 15:05:17 +0000 Subject: [PATCH 6/6] leo: fix review feedback on health enrichments PR #1752 - What: restore evidence lost during rebase, remove duplicate enrichment blocks, fix source archive YAML, strip [[...]] from source refs, downgrade AI scribes confidence to likely - Why: rebase created duplicate blocks and lost Aon 192K analysis, India generics data, MACE adherence data, and reconciliation bill evidence. Archives had duplicate processed_by/Key Facts sections. - Restored: Aon front-loaded cost analysis, India patent expiry generics, 47% MACE hospitalization adherence data, site-neutral FQHC threat - Removed: duplicate lifestyle-modification blocks in GLP-1 claims, duplicate OpenEvidence valuation in funding claim, duplicate Epic challenge in scribes claim, duplicate produce-prescriptions in SDOH - Fixed: 4 archive files with duplicate YAML frontmatter and Key Facts Pentagon-Agent: Leo --- ...e is immediate unambiguous and low-risk.md | 9 ++----- ...constraint between headcount and output.md | 4 +-- ...t cost impact inflationary through 2035.md | 11 +++++--- ...of US physicians daily within two years.md | 4 +-- ...astructure connects screening to action.md | 6 ++--- ...ients-undermining-chronic-use-economics.md | 4 +-- ...ercent of deals are flat or down rounds.md | 7 +---- ...iagnostic accuracy in randomized trials.md | 4 +-- ... four independent methodologies confirm.md | 4 +-- ...ce-prescriptions-diabetes-care-critique.md | 9 ------- ...idence-clinical-ai-growth-12b-valuation.md | 16 ----------- ...arting-ambient-scribe-market-disruption.md | 12 --------- ...modification-efficacy-combined-approach.md | 27 +------------------ 13 files changed, 25 insertions(+), 92 deletions(-) diff --git a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md index 45e141c32..597d0dd32 100644 --- a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md +++ b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md @@ -2,7 +2,7 @@ type: claim domain: health description: "92% of US health systems deploying AI scribes by March 2025 — a 2-3 year adoption curve vs 15 years for EHRs — because documentation is the one clinical workflow where AI improvement is immediately measurable, carries minimal patient risk, and delivers revenue capture gains" -confidence: proven +confidence: likely source: "Bessemer Venture Partners, State of Health AI 2026 (bvp.com/atlas/state-of-health-ai-2026)" created: 2026-03-07 --- @@ -51,16 +51,11 @@ WVU Medicine expanded Abridge ambient AI across 25 hospitals including rural fac ### Additional Evidence (challenge) -*Source: [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] | Added: 2026-03-18* +*Source: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption | Added: 2026-03-18* Epic's AI Charting launch (Feb 2026) threatens to commoditize the ambient documentation beachhead that standalone AI companies used to establish clinical trust. Epic's 42% acute hospital market share and native EHR integration create 'good enough' dynamics where technical superiority matters less than bundled convenience. Early pilots show Epic comparable on simple notes but behind on complex specialties, suggesting the high-adoption documentation use case is splitting into commodity (Epic-captured) and premium (specialty-focused) segments. This challenges the interpretation that scribe adoption = sustainable moat—the beachhead may be rapidly commoditized by platform incumbents. -### Additional Evidence (challenge) -*Source: [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] | Added: 2026-03-19* - -Epic's February 2026 AI Charting launch threatens to commoditize the documentation beachhead. While AI scribes achieved 92% provider adoption, Epic's native integration advantage (full patient history access, single-vendor IT preference, add-on pricing vs. millions in standalone contracts) means the 'easy adoption' use case may not translate to sustainable competitive moats. Abridge CEO Shiv Rao is repositioning the company as 'more than an AI scribe' by pursuing prior authorization and clinical decision support, suggesting the documentation-only market is now contested. The high adoption rate may have been a function of being first to an undefended use case rather than a durable advantage. - --- Relevant Notes: diff --git a/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md b/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md index 2d87913d0..0f59c5330 100644 --- a/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md +++ b/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md @@ -40,13 +40,13 @@ BVP reports AI-native healthcare companies achieve $500K-$1M+ ARR per FTE with 7 ### Additional Evidence (challenge) -*Source: [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] | Added: 2026-03-18* +*Source: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption | Added: 2026-03-18* Abridge's productivity premium may not survive platform commoditization. Despite being KLAS #1 ambient scribe with 150+ health system deployments, Epic's native AI Charting threatens Abridge's core documentation revenue through integration advantages and 'good enough' quality at lower switching costs. Abridge is repositioning toward clinical decision support and prior authorization—higher-value use cases Epic hasn't matched—suggesting the productivity premium only holds when the AI company can stay ahead of platform commoditization cycles. ### Additional Evidence (challenge) -*Source: [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] | Added: 2026-03-19* +*Source: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption | Added: 2026-03-19* Epic's platform commoditization of AI scribes suggests the productivity premium may not survive when incumbents add 'good enough' AI to existing workflows. Abridge's 150+ health system deployments and best-in-class accuracy face pressure from Epic's native integration, which doesn't require matching quality—just being sufficient for most documentation use cases. If platform incumbents can capture high-volume segments with lower-quality but better-integrated AI, the revenue productivity advantage may only persist in high-complexity niches where integration advantages don't overcome the quality gap. diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 3c392007c..10e716e0e 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -115,15 +115,15 @@ International generic competition beginning January 2026 (Canada patent expiry, ### Additional Evidence (challenge) -*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* +*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19* If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy. ### Additional Evidence (challenge) -*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* +*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19* -If GLP-1 + exercise combination creates durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone) that persists after discontinuation, the chronic use economic model may be unnecessarily pessimistic. Value could accrue from shorter medication courses paired with intensive behavioral support, reducing long-term pharmaceutical spend while maintaining clinical benefits. +Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded and time-limited: costs rise 23% vs 10% in year 1, but after 12 months medical costs grow just 2% vs 6% for non-users. At 30 months for diabetes patients, medical cost growth is 6-9 percentage points lower. This suggests the 'inflationary through 2035' claim may be true only for short-term payers who never capture the year-2+ savings, while long-term risk-bearers see net cost reduction. The inflationary impact depends on payment model structure, not just the chronic use model itself. --- @@ -137,6 +137,11 @@ Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on US patent protection extends to 2031-2033 for Ozempic and Wegovy, creating a legal wall that prevents approved generic competition until then. The compounding pharmacy channel that provided affordable access during 2023-2025 closed in February 2025 when FDA removed semaglutide from the shortage list. This means the US will remain 'inflationary' through legal channels through 2031-2033, but gray market pressure from $15/month Indian generics versus $1,200/month Wegovy will create illegal importation at scale. +### Additional Evidence (challenge) +*Source: 2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics | Added: 2026-03-20* + +India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033. + ### Additional Evidence (challenge) *Source: 2026-03-22-health-canada-rejects-dr-reddys-semaglutide | Added: 2026-03-22* diff --git a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md index a9b681e52..0b1cfc124 100644 --- a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md +++ b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md @@ -19,13 +19,13 @@ The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveragin ### Additional Evidence (extend) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* +*Source: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation | Added: 2026-03-18* OpenEvidence scale as of January 2026: 20M clinical consultations/month (up from 8.5M in 2025, representing 2,000%+ YoY growth), valuation increased from $3.5B to $12B in months, reached 1M consultations in a single day (March 10, 2026 milestone), used across 10,000+ hospitals. First AI to score 100% on all parts of USMLE. Despite this scale, 44% of physicians remain concerned about accuracy/misinformation and 19% about lack of oversight/explainability—trust barriers persist even among heavy users. ### Additional Evidence (extend) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19* +*Source: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation | Added: 2026-03-19* OpenEvidence reached 20M clinical consultations/month by January 2026 (up from 8.5M in 2025, representing 2,000%+ YoY growth). On March 10, 2026, OpenEvidence became the first AI system to reach 1M clinical consultations in a single day. The platform is now used across 10,000+ hospitals and medical centers nationwide. Valuation tripled from $3.5B to $12B in under 12 months, with a $250M Series D led by Thrive Capital and DST Global in January 2026. diff --git a/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md b/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md index 522304e92..cc62ba37c 100644 --- a/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md +++ b/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md @@ -43,15 +43,15 @@ Community health worker programs demonstrate the same payment boundary stall: on ### Additional Evidence (challenge) -*Source: [[2025-01-01-produce-prescriptions-diabetes-care-critique]] | Added: 2026-03-18* +*Source: 2025-01-01-produce-prescriptions-diabetes-care-critique | Added: 2026-03-18* The Diabetes Care perspective challenges the 'strong ROI' claim for SDOH interventions by questioning whether produce prescriptions—a specific SDOH intervention—actually produce clinical outcomes. The observational evidence showing improvements may reflect methodological artifacts (self-selection, regression to mean) rather than true causal effects. This suggests the ROI evidence for SDOH interventions may be weaker than claimed, particularly for single-factor interventions like food provision. ### Additional Evidence (challenge) -*Source: [[2025-01-01-produce-prescriptions-diabetes-care-critique]] | Added: 2026-03-19* +*Source: 2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026 | Added: 2026-03-20* -The ADA's Diabetes Care journal questions whether produce prescriptions—a specific SDOH intervention type—generate clinical benefit despite improving food security metrics. Observational studies show diet quality improvements but lack controlled evidence for HbA1c reduction. Programs enrolling patients with very poor baseline control (HbA1c >9%) show improvements that may reflect regression to the mean rather than intervention effect. The clinical diabetes community is signaling that 'food as medicine' framing has outrun the evidence base for this intervention category. +The RSC's second reconciliation bill proposes site-neutral payments that would eliminate the enhanced FQHC reimbursement rates (~$300/visit vs ~$100/visit) that fund CHW programs. Combined with OBBBA's Medicaid cuts, this creates a two-vector attack on the institutional infrastructure that hosts most CHW programs. The challenge is not just documentation and operational infrastructure—the payment foundation itself is under legislative threat. Even if Z-code documentation improved and operational infrastructure was built, the revenue model that makes CHW programs economically viable within FQHCs would be eliminated by site-neutral payments. --- diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index a59269ef9..192f277ca 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -97,7 +97,7 @@ GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacol ### Additional Evidence (extend) -*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* +*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19* Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise reduces regain to 3.5 kg. This suggests the low persistence rates may be economically rational from a patient perspective if medication alone provides no durable benefit—patients who discontinue without establishing exercise habits return to baseline regardless of medication duration. @@ -105,7 +105,7 @@ Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than pla ### Additional Evidence (extend) *Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19* -Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise (3.5 kg regain) maintains 60% more weight loss. This suggests the adherence paradox may be misframed—the economic value may not require chronic medication use if behavioral interventions create durable change that outlasts pharmacotherapy. +Aon data shows benefits scale dramatically with adherence: for diabetes patients, medical cost growth is 6 percentage points lower at 30 months overall, but 9 points lower with 80%+ adherence. For weight loss patients, cost growth is 3 points lower at 18 months overall, but 7 points lower with consistent use. Adherent users (80%+) show 47% fewer MACE hospitalizations for women and 26% for men. This confirms that adherence is the binding variable—the 80%+ adherent cohort shows the strongest effects across all outcomes, making low persistence rates even more economically damaging. --- diff --git a/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md b/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md index f829c9673..a531c2268 100644 --- a/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md +++ b/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md @@ -27,16 +27,11 @@ Abridge raised $300M Series E at $5B valuation and Ambiance raised $243M Series ### Additional Evidence (confirm) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* +*Source: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation | Added: 2026-03-18* OpenEvidence valuation trajectory demonstrates winner-take-most dynamics: $3.5B → $6B → $12B in under 12 months, with $250M Series D led by Thrive Capital and DST Global. This 3.4x valuation increase in months while 35% of healthcare AI deals are flat/down rounds confirms capital concentration in category leaders. -### Additional Evidence (confirm) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19* - -OpenEvidence valuation trajectory demonstrates extreme winner-take-most dynamics: $3.5B → $6B → $12B in under 12 months, with a $250M Series D in January 2026. This represents the fastest capital absorption in clinical AI history, with valuation tripling while the broader market shows 35% of deals at flat or down rounds. OpenEvidence is capturing category-defining capital velocity in clinical reasoning AI, separate from the ambient scribe market. - --- ### Additional Evidence (confirm) diff --git a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md index 0e61caa9b..944a01cc4 100644 --- a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md +++ b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md @@ -19,13 +19,13 @@ The implication for AI deployment strategy: the highest-value clinical AI applic ### Additional Evidence (challenge) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* +*Source: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation | Added: 2026-03-18* OpenEvidence achieved 100% USMLE score (first AI in history) and is now deployed at 20M consultations/month across 40%+ of US physicians, creating the first large-scale empirical test of whether benchmark performance translates to population health outcomes. The absence of published outcomes data at this deployment scale represents a critical evidence gap—if benchmark performance doesn't translate to clinical impact, we should see evidence of that at 20M monthly consultations. ### Additional Evidence (challenge) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19* +*Source: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation | Added: 2026-03-19* OpenEvidence became the first AI in history to score 100% on all parts of the USMLE, exceeding any human score on the most challenging medical licensing exam. This creates an empirical test case: OpenEvidence is now deployed at scale (20M consultations/month, 40%+ of US physicians daily) with perfect benchmark performance, yet no peer-reviewed outcomes data demonstrates whether this translates to improved patient outcomes. The absence of outcomes data at this scale represents a critical gap in validating whether benchmark performance predicts clinical impact. diff --git a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md index 14bc59c0f..bce7aa65f 100644 --- a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md +++ b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md @@ -55,7 +55,7 @@ While social determinants predict health outcomes in observational studies, RCT ### Additional Evidence (extend) -*Source: [[2025-01-01-produce-prescriptions-diabetes-care-critique]] | Added: 2026-03-18* +*Source: 2025-01-01-produce-prescriptions-diabetes-care-critique | Added: 2026-03-18* The Diabetes Care perspective provides a specific mechanism example: produce prescription programs may improve food security (a social determinant) without improving clinical outcomes (HbA1c, diabetes control) because the causal pathway from social disadvantage to disease is not reversible through single-factor interventions. This demonstrates the 10-20% medical care contribution in practice—addressing one SDOH factor (food access) doesn't overcome the compound effects of poverty, stress, and social disadvantage. @@ -67,7 +67,7 @@ Amodei's complementary factors framework explicitly identifies 'human constraint ### Additional Evidence (extend) -*Source: [[2025-01-01-produce-prescriptions-diabetes-care-critique]] | Added: 2026-03-19* +*Source: 2025-01-01-produce-prescriptions-diabetes-care-critique | Added: 2026-03-19* The produce prescription evidence gap illustrates the mechanism: knowing that social factors (food quality) drive health outcomes doesn't automatically mean that interventions targeting those factors (food vouchers) improve health. Food insecurity may be a proxy for poverty/stress/disadvantage rather than a direct causal factor. The ADA perspective shows that even when the correlation between social factors and health is proven, the causal pathway for interventions remains uncertain—food provision may improve food security without improving clinical outcomes if the underlying social determinants remain unaddressed. diff --git a/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md b/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md index ce955afd1..7454bb4d0 100644 --- a/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md +++ b/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md @@ -14,10 +14,6 @@ processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md"] extraction_model: "anthropic/claude-sonnet-4.5" -processed_by: vida -processed_date: 2026-03-19 -enrichments_applied: ["SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md"] -extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -79,8 +75,3 @@ EXTRACTION HINT: The distinction between "food matters for health" (proven) and - The American Diabetes Association's journal is questioning the evidence standard for produce prescriptions -## Key Facts -- Diabetes Care published 'Food Is Medicine, but Are Produce Prescriptions?' perspective in 2023 -- Observational produce prescription evaluations include multisite 9-program studies and Recipe4Health -- Programs showing HbA1c improvements typically enroll patients with baseline HbA1c >9% -- The American Diabetes Association is the publisher of Diabetes Care journal diff --git a/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md b/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md index 0bd1728dc..2c958d9d3 100644 --- a/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md +++ b/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md @@ -14,10 +14,6 @@ processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md"] extraction_model: "anthropic/claude-sonnet-4.5" -processed_by: vida -processed_date: 2026-03-19 -enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md", "AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md"] -extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -78,18 +74,6 @@ WHY ARCHIVED: Significant scale update — the existing claim understates 2026 m EXTRACTION HINT: Update the existing claim with scale metrics, but flag the benchmark-to-outcomes translation tension as a challenge to both the OpenEvidence claim and the benchmark performance claim -## Key Facts -- OpenEvidence reached 8.5M clinical consultations/month in 2025 -- OpenEvidence reached 20M clinical consultations/month by January 2026 -- OpenEvidence valuation: $3.5B → $6B → $12B in under 12 months -- OpenEvidence Series D: $250M led by Thrive Capital and DST Global (January 2026) -- OpenEvidence first AI to score 100% on USMLE (all parts) -- OpenEvidence used across 10,000+ hospitals and medical centers -- March 10, 2026: OpenEvidence reached 1M consultations in one day -- 44% of physicians concerned about OpenEvidence accuracy/misinformation risk -- 19% of physicians concerned about lack of physician oversight/explainability - - ## Key Facts - OpenEvidence reached 8.5M clinical consultations/month in 2025 - OpenEvidence reached 20M clinical consultations/month by January 2026 diff --git a/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md b/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md index 6c52d13de..9f4318347 100644 --- a/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md +++ b/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md @@ -15,10 +15,6 @@ processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md", "AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md"] extraction_model: "anthropic/claude-sonnet-4.5" -processed_by: vida -processed_date: 2026-03-19 -enrichments_applied: ["AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md", "AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md"] -extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -85,11 +81,3 @@ EXTRACTION HINT: The "good enough" dynamic is the key claim — extract that as - Standalone scribe contracts can reach millions annually for health systems -## Key Facts -- Epic Systems controls 42% of acute hospital EHR market share as of Feb 2026 -- Epic covers 55% of US hospital beds -- Abridge won top ambient scribe slot in 2025 KLAS annual report -- Abridge has 150+ health system deployments as of Feb 2026 -- Ambient scribe market estimated at $2B -- Standalone AI scribe contracts can reach millions annually for health systems -- Early Epic AI Charting pilots show comparable performance on simple note types, significantly behind on complex specialties diff --git a/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md b/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md index d068c7334..97aad2958 100644 --- a/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md +++ b/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md @@ -14,14 +14,6 @@ processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] extraction_model: "anthropic/claude-sonnet-4.5" -processed_by: vida -processed_date: 2026-03-19 -enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] -extraction_model: "anthropic/claude-sonnet-4.5" -processed_by: vida -processed_date: 2026-03-19 -enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] -extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -94,24 +86,7 @@ EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison - Meta-analysis of 22 RCTs with 2,258 participants found ~25% of GLP-1 weight loss is lean mass - Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced - Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of weight loss interventions -- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication) -- BALANCE model includes lifestyle support component but specific exercise programming details not specified in source - - -## Key Facts -- WHO December 2025 guidelines specifically recommend GLP-1 therapies 'combined with intensive behavioral therapy to maximize and sustain benefits' -- Meta-analysis of 22 RCTs with 2,258 participants found approximately 25% of GLP-1 weight loss is lean mass -- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced -- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of weight loss interventions - At week 52 all intervention groups regained weight after stopping; by week 104: placebo +7.6 kg, liraglutide only +8.7 kg, exercise only +5.4 kg, combination +3.5 kg - Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication) - ADA notes new therapies claiming 'enhanced quality of weight loss by improving muscle preservation' but no FDA-approved compounds with proven muscle preservation yet - - -## Key Facts -- Meta-analysis of 22 RCTs with 2,258 participants found approximately 25% of GLP-1 weight loss is lean mass -- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced -- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of interventions -- WHO December 2025 guidelines recommend GLP-1 therapies 'combined with intensive behavioral therapy' -- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary, not FDA-approved) -- Weight regain by week 104: placebo +7.6 kg, liraglutide only +8.7 kg, exercise only +5.4 kg, combination +3.5 kg +- BALANCE model includes lifestyle support component but specific exercise programming details not specified in source -- 2.45.2